Clinical Trials Browser

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04256707 2025-03-19

SPRINT

Phase 1/2 Completed

126 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Phase NA Recruiting

30 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03193437 2023-02-16

SELECT

Phase 2 Terminated

8 enrolled 11 charts

Thoracic

Thymoma

NCT03466827 2018-03-15

TET-SEL

Phase 2 Unknown

25 enrolled

Thoracic

Thymoma

NCT02351505 2016-05-16

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 6 charts

Thoracic

Small Cell Lung Carcinoma